

Kevin L Winthrop

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4259509/publications.pdf>

Version: 2024-02-01

227
papers

24,428
citations

13865

67
h-index

7518

151
g-index

232
all docs

232
docs citations

232
times ranked

19111
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry"™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e138-e138.	0.9	4
2	Response to: "Correspondence on "Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab"™"™ by Tampe<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e133-e133.	0.9	5
3	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5%years. <i>Modern Rheumatology</i> , 2023, 33, 64-72.	1.8	2
4	Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 85-96.	1.9	7
5	Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States. <i>Chest</i> , 2022, 161, 365-369.	0.8	1
6	The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment. <i>Journal of Rheumatology</i> , 2022, 49, 225-229.	2.0	9
7	Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 335-343.	0.9	71
8	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 184-192.	0.9	40
9	Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 206-213.	0.9	25
10	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e178-e190.	9.1	51
11	COVID-19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings. <i>Arthritis and Rheumatology</i> , 2022, 74, 1091-1092.	5.6	9
12	Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 162-172.	0.8	8
13	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.9	89
14	Oral surveillance and JAK inhibitor safety: the theory of relativity. <i>Nature Reviews Rheumatology</i> , 2022, 18, 301-304.	8.0	91
15	Nontuberculous Mycobacteria. <i>Clinics in Chest Medicine</i> , 2022, 43, 89-98.	2.1	10
16	Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study. <i>RMD Open</i> , 2022, 8, e002110.	3.8	5
17	COVID-19 Update for the GRAPPA 2021 Annual Meeting: Focus on COVID-19 Vaccination. <i>Journal of Rheumatology</i> , 2022, , jrheum.211319.	2.0	2
18	In the shadow of antibodies: how T cells defend against COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 757-759.	0.9	2

#	ARTICLE	IF	CITATIONS
19	Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. <i>Rheumatology and Therapy</i> , 2022, 9, 521-539.	2.3	18
20	Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. <i>Rheumatology and Therapy</i> , 2022, 9, 243-263.	2.3	7
21	Functional, transcriptional, and microbial shifts associated with healthy pulmonary aging in rhesus macaques. <i>Cell Reports</i> , 2022, 39, 110725.	6.4	7
22	P196 Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis. <i>Rheumatology</i> , 2022, 61, .	1.9	1
23	P220 Long-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. <i>Rheumatology</i> , 2022, 61, .	1.9	1
24	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 914-929.	1.3	29
25	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
26	SARS CoV-2 infection among patients using immunomodulatory therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 269-271.	0.9	29
27	The Effect of HLA-B27 on Susceptibility and Severity of COVID-19. <i>Journal of Rheumatology</i> , 2021, 48, 621-622.	2.0	19
28	Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corona RA registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 134-136.	0.9	22
29	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e1-e12.	5.6	201
30	Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 304-311.	0.9	129
31	Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 161-163.	1.2	13
32	Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. <i>Journal of Rheumatology</i> , 2021, 48, 1230-1238.	2.0	29
33	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201671.	2.0	6
34	Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1102-1104.	0.9	12
35	Rheumatology and COVID-19 at 1 year: facing the unknowns. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 679-681.	0.9	12
36	Validity of Diagnosis Code-Based Claims to Identify Pulmonary NTM Disease in Bronchiectasis Patients. <i>Emerging Infectious Diseases</i> , 2021, 27, 982-985.	4.3	12

#	ARTICLE	IF	CITATIONS
37	COVID-19 vaccination and antirheumatic therapy. <i>Rheumatology</i> , 2021, 60, 3496-3502.	1.9	89
38	COVID-19 pandemic management and the rheumatology patient. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101663.	3.3	3
39	OO9â€fSafety profile of baricitinib for the treatment of RA up to 8.4 years: an updated integrated safety analysis. <i>Rheumatology</i> , 2021, 60, .	1.9	1
40	HLA-B27 is associated with reduced disease activity in axial spondyloarthritis. <i>Scientific Reports</i> , 2021, 11, 12331.	3.3	7
41	The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know. <i>Journal of Rheumatology</i> , 2021, 48, 1201-1204.	2.0	5
42	Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections). <i>Current Rheumatology Reports</i> , 2021, 23, 74.	4.7	17
43	Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1255-1265.	0.9	77
44	The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy. <i>Annals of Internal Medicine</i> , 2021, 174, 1510-1518.	3.9	18
45	SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1249-1251.	0.9	6
46	Screening for Chlamydial and Gonococcal Infections. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 957.	7.4	18
47	Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis. <i>American Journal of Audiology</i> , 2021, 30, 800-809.	1.2	8
48	Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
49	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , 2020, 30, 36-43.	1.8	44
50	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.9	63
51	â€Lady Windermere's counterpart? Pulmonary nontuberculous mycobacteria in men with bronchiectasis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114916.	1.8	5
52	Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials. <i>Clinical Rheumatology</i> , 2020, 39, 375-379.	2.2	22
53	Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008â€“2015. <i>Annals of the American Thoracic Society</i> , 2020, 17, 178-185.	3.2	159
54	Preliminary validation of the NTM Module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease. <i>European Respiratory Journal</i> , 2020, 55, 1901300.	6.7	13

#	ARTICLE	IF	CITATIONS
55	Chronic Inguinal Lymphadenitis in a Patient With Rheumatoid Arthritis Being Treated With Tofacitinib. <i>Journal of Clinical Rheumatology</i> , 2020, 26, e138-e139.	0.9	1
56	P220 An updated safety profile of baricitinib for the treatment of RA up to 7 years. <i>Rheumatology</i> , 2020, 59, .	1.9	1
57	Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1532-1543.	0.9	23
58	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	3.8	36
59	Reply to: "Do IL-17 inhibitors increase risk of respiratory tract infections?" <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e305-e306.	1.2	0
60	In response to: "Reply to research letter" <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e445.	1.2	0
61	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2020, 72, e1-e12.	5.6	64
62	To immunosuppress: whom, when and how? That is the question with COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1129-1131.	0.9	16
63	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1290-1297.	0.9	61
64	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, 905-913.	5.8	357
65	<i>Mycobacterium avium</i> Complex: Addressing Gaps in Diagnosis and Management. <i>Journal of Infectious Diseases</i> , 2020, 222, S199-S211.	4.0	34
66	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i> , 2020, 6, e001395.	3.8	100
67	The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 677-679.	1.2	46
68	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. <i>Lancet Rheumatology</i> , The, 2020, 2, e347-e357.	3.9	51
69	Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001095.	3.8	48
70	Biologics, spondylitis and COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1663-1665.	0.9	25
71	Mycobacterial Infections Potentiated by Biologics. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 413-423.	5.1	4
72	Who Needs a Corona?. <i>Arthritis and Rheumatology</i> , 2020, 72, 874-876.	5.6	5

#	ARTICLE	IF	CITATIONS
73	Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 573-580.	0.9	17
74	Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1665-1666.	0.9	2
75	The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1523-1526.	1.2	21
76	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>European Respiratory Journal</i> , 2020, 56, 2000535.	6.7	336
77	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, e1-e36.	5.8	367
78	An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. <i>Drug Safety</i> , 2020, 43, 379-392.	3.2	28
79	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. <i>Arthritis and Rheumatology</i> , 2020, 72, 1241-1251.	5.6	142
80	Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 669-671.	0.9	12
81	Nutrition and Markers of Disease Severity in Patients With Bronchiectasis. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 390-403.	0.7	3
82	The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 695-703.	1.3	26
83	Mycobacteria and immunosuppression. <i>Handbook of Systemic Autoimmune Diseases</i> , 2020, 16, 83-107.	0.1	2
84	Practice Patterns of Pneumocystis Pneumonia Prophylaxis in Connective Tissue Diseases: A Survey of Infectious Disease Physicians. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz315.	0.9	7
85	Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. <i>RMD Open</i> , 2019, 5, e000942.	3.8	45
86	The Interface Between Digital Health and Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, xv-xvi.	1.9	0
87	In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis. <i>Current Rheumatology Reports</i> , 2019, 21, 36.	4.7	15
88	Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. <i>European Respiratory Journal</i> , 2019, 54, 1801896.	6.7	31
89	Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. <i>Arthritis Research and Therapy</i> , 2019, 21, 102.	3.5	43
90	A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1755-1766.	1.9	201

#	ARTICLE	IF	CITATIONS
91	Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative Outcomes. <i>Arthritis Care and Research</i> , 2019, 71, 1224-1233.	3.4	20
92	Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty. <i>Annals of Internal Medicine</i> , 2019, 171, 680.	3.9	12
93	Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty. <i>Annals of Internal Medicine</i> , 2019, 170, 825.	3.9	47
94	THU0078â€¦SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. , 2019, , .		5
95	THU0167â€¦SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM. , 2019, , .		10
96	FRIO164â€¦INCIDENCE RATE AND CHARACTERIZATION OF HERPES ZOSTER IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: AN UPDATE FROM BARICITINIB CLINICAL STUDIES. , 2019, , .		1
97	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. <i>Journal of Rheumatology</i> , 2019, 46, 7-18.	2.0	207
98	Longâ€¦Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Fiveâ€¦Year Observational Study. <i>Arthritis Care and Research</i> , 2019, 71, 993-1003.	3.4	24
99	Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 282-284.	0.9	15
100	Risk for Herpes Zoster in Tofacitinibâ€¦Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids. <i>Arthritis Care and Research</i> , 2019, 71, 1249-1254.	3.4	71
101	Immune Dysfunction and Nontuberculous Mycobacterial Disease. <i>Respiratory Medicine</i> , 2019, , 111-130.	0.1	1
102	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.9	36
103	RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. <i>European Respiratory Journal</i> , 2018, 51, 1702052.	6.7	146
104	RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. <i>European Respiratory Journal</i> , 2018, 51, 1702053.	6.7	144
105	Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2018-213222.	0.9	131
106	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. <i>European Respiratory Journal</i> , 2018, 51, 1800170.	6.7	159
107	805. Amikacin Liposome Inhalation Suspension (ALIS) Add-on Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion. <i>Open Forum Infectious Diseases</i> , 2018, 5, S288-S289.	0.9	2
108	122. All-Cause Mortality Increased With Nontuberculous Mycobacterial Lung Disease in US Medicare. <i>Open Forum Infectious Diseases</i> , 2018, 5, S7-S7.	0.9	0

#	ARTICLE	IF	CITATIONS
109	780. Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in US Medicare, 2008–2015. <i>Open Forum Infectious Diseases</i> , 2018, 5, S279-S280.	0.9	1
110	Association between Inhaled Corticosteroid Use and Pulmonary Nontuberculous Mycobacterial Infection. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1169-1176.	3.2	47
111	Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. <i>Chest</i> , 2018, 154, 1311-1320.	0.8	57
112	Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2258-2265.	1.9	175
113	T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1149-1155.e1.	1.2	28
114	Treatment of Mycobacterium abscessus Complex. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 362-376.	2.1	55
115	Mycobacterial Disease: Evolving Concepts. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 269-269.	2.1	0
116	Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration. <i>PLoS ONE</i> , 2018, 13, e0197976.	2.5	35
117	Advances in safety management of targeted therapies for rheumatoid arthritis. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, SY61-4.	0.0	0
118	On the Reportability of Nontuberculous Mycobacterial Disease to Public Health Authorities. <i>Annals of the American Thoracic Society</i> , 2017, 14, 314-317.	3.2	23
119	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 543-546.	0.9	154
120	The emerging safety profile of JAK inhibitors in rheumatic disease. <i>Nature Reviews Rheumatology</i> , 2017, 13, 234-243.	8.0	420
121	Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. <i>Journal of Rheumatology</i> , 2017, 44, 565-570.	2.0	9
122	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1253-1262.	0.9	316
123	Mortality after Respiratory Isolation of Nontuberculous Mycobacteria: A Comparison of Patients Who Did and Did Not Meet Disease Criteria. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1112-1119.	3.2	32
124	Long-Term Outcomes in a Population-based Cohort with Respiratory Nontuberculous Mycobacteria Isolation. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1120-1128.	3.2	17
125	The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. <i>Contemporary Clinical Trials</i> , 2017, 58, 78-85.	1.8	39
126	Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis. <i>Chest</i> , 2017, 152, 1120-1127.	0.8	36

#	ARTICLE	IF	CITATIONS
127	Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1559-1565.	0.9	108
128	Biosimilar switching – To set a form upon desired change. <i>Nature Reviews Rheumatology</i> , 2017, 13, 391-392.	8.0	9
129	The role of IL-6 in host defence against infections: immunobiology and clinical implications. <i>Nature Reviews Rheumatology</i> , 2017, 13, 399-409.	8.0	303
130	Pathogens and antibiotic sensitivities in endophthalmitis. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 481-488.	2.6	30
131	The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 1969-1977.	5.6	103
132	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. <i>Arthritis and Rheumatology</i> , 2017, 69, 1960-1968.	5.6	182
133	Herpes zoster in psoriasis patients treated with tofacitinib. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 302-309.	1.2	57
134	Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 814-823.	5.6	212
135	Vaccines and Disease-Modifying Antirheumatic Drugs. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 1-13.	1.9	53
136	Adult Patients With Bronchiectasis. <i>Chest</i> , 2017, 151, 982-992.	0.8	282
137	Infection and Malignancy in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, xiii-xiv.	1.9	1
138	Pulmonary Nontuberculous Mycobacteria – Associated Deaths, Ontario, Canada, 2001 – 2013. <i>Emerging Infectious Diseases</i> , 2017, 23, 468-476.	4.3	64
139	Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. <i>Arthritis Research and Therapy</i> , 2017, 19, 276.	3.5	10
140	Surveillance of Extrapulmonary Nontuberculous Mycobacteria Infections, Oregon, USA, 2007 – 2012. <i>Emerging Infectious Diseases</i> , 2017, 23, 1627-1630.	4.3	34
141	Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 1, 128-137.	0.7	8
142	Comparative Infectious Risk of Immunosuppressive Therapies Used in Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 2, 44-50.	0.7	1
143	Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. <i>Arthritis and Rheumatology</i> , 2016, 68, 2328-2337.	5.6	150
144	Diabetes as an increasingly common comorbidity among patient hospitalizations for tuberculosis in the USA. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000268.	2.8	4

#	ARTICLE	IF	CITATIONS
145	Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1843-1847.	0.9	215
146	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.9	258
147	Treatments for Lupus Nephritis: A Systematic Review and Network Metaanalysis. <i>Journal of Rheumatology</i> , 2016, 43, 1801-1815.	2.0	28
148	Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. <i>Annals of the American Thoracic Society</i> , 2016, 13, S379-S384.	3.2	58
149	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. <i>Thorax</i> , 2016, 71, 88-90.	5.6	274
150	A Rhesus Macaque Model of Pulmonary Nontuberculous Mycobacterial Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 170-176.	2.9	13
151	Comparative Effectiveness of Antibiotic Prophylaxis in Cataract Surgery. <i>Ophthalmology</i> , 2016, 123, 287-294.	5.2	103
152	Vaccinations for rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 330-336.	4.3	22
153	Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. <i>Arthritis and Rheumatology</i> , 2016, 68, 56-66.	5.6	136
154	Infection Risk and Safety of Corticosteroid Use. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 157-176.	1.9	307
155	The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 687-695.	0.9	166
156	Influenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink. <i>PLoS ONE</i> , 2016, 11, e0153848.	2.5	46
157	BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 347.	3.5	6
158	Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2015, 17, 136.	3.5	13
159	Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: Data from the international COMORA cohort. <i>Vaccine</i> , 2015, 33, 1446-1452.	3.8	96
160	The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. <i>European Respiratory Journal</i> , 2015, 45, 1177-1179.	6.7	62
161	Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012. <i>Annals of the American Thoracic Society</i> , 2015, 12, 642-647.	3.2	131
162	Nontuberculous Mycobacteria Infections in Immunosuppressed Hosts. <i>Clinics in Chest Medicine</i> , 2015, 36, 91-99.	2.1	219

#	ARTICLE	IF	CITATIONS
163	E34.â€fVaccination Uptake in Patients with Rheumatoid Arthritis Treated with Disease-Modifying Anti-Rheumatic Drug Therapy: A Retrospective Cohort Study using UK Primary Care Electronic Medical Records. <i>Rheumatology</i> , 2015, , .	1.9	0
164	The challenge of pulmonary nontuberculous mycobacterial infection. <i>Current Pulmonology Reports</i> , 2015, 4, 152-161.	1.3	15
165	Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Diseaseâ€Modifying Therapy. <i>Arthritis Care and Research</i> , 2015, 67, 731-736.	3.4	94
166	Variable agreement among experts regarding <scp><i>M</i></scp><i>ycobacterium avium</i> complex lung disease. <i>Respirology</i> , 2015, 20, 348-351.	2.3	17
167	Reply to: â€œComment on â€Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitorsâ€™â€•. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e125-e126.	1.2	3
168	Disseminated Mycobacterial Infection After International Medical Tourism. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv054.	0.9	5
169	Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1065-1071.	0.9	79
170	Infections and biologic therapy for rheumatoid arthritis. , 2015, , 530-535.		0
171	Persistence of <i>Staphylococcus aureus</i> colonization among individuals with immune-mediated inflammatory diseases treated with TNF-Â inhibitor therapy. <i>Rheumatology</i> , 2014, 53, 332-337.	1.9	19
172	Opinions Differ by Expertise in <i>Mycobacterium avium</i> Complex Disease. <i>Annals of the American Thoracic Society</i> , 2014, 11, 17-22.	3.2	15
173	Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2675-2684.	5.6	290
174	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 529-535.	0.9	456
175	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.9	1,688
176	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 62-68.	0.9	659
177	Vaccinations for Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 431.	4.7	32
178	Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAFETY Assessment of Biologic ThERapy (SABER) Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1942-1948.	0.9	100
179	Association Between the Initiation of Antiâ€Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 887.	7.4	187
180	Review and Update on the Epidemiology, Clinical Presentation, Diagnosis, and Treatment of Fungal Keratitis. <i>Current Fungal Infection Reports</i> , 2013, 7, 293-300.	2.6	18

#	ARTICLE	IF	CITATIONS
181	“Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study” BMC Infectious Diseases, 2013, 13, 533.	2.9	11
182	Physician Attitudes Regarding School-located Vaccination Clinics. Journal of School Health, 2013, 83, 299-305.	1.6	6
183	Reply. American Journal of Ophthalmology, 2013, 156, 408.	3.3	0
184	Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nature Reviews Rheumatology, 2013, 9, 524-531.	8.0	49
185	Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. Journal of Cataract and Refractive Surgery, 2013, 39, 8-14.	1.5	145
186	Initiation of Anti-TNF Therapy and the Risk of Optic Neuritis: From the Safety Assessment of Biologic Therapy (SABER) Study. American Journal of Ophthalmology, 2013, 155, 183-189.e1.	3.3	60
187	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.9	102
188	Update on the Epidemiology of Pulmonary Nontuberculous Mycobacterial Infections. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 087-094.	2.1	179
189	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1. Annals of the Rheumatic Diseases, 2013, 72, ii2-ii34.	0.9	114
190	Environment or Host?. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 684-691.	5.6	109
191	You can't always get what you want, but if you try sometimes (with two tests—TST and IGRA—for Tj ETQq1 1 0,784314 rgBT /Over	0.9	64
192	Risk factors associated with pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 2012, 18, 233-240.	2.6	60
193	Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases. JAMA - Journal of the American Medical Association, 2012, 308, 43-9.	7.4	246
194	Infections and Biologic Therapy in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2012, 38, 727-745.	1.9	52
195	Patients with nontuberculous mycobacteria: comparison of updated and previous diagnostic criteria for lung disease. Diagnostic Microbiology and Infectious Disease, 2012, 74, 98-100.	1.8	12
196	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 625-639.	3.4	1,413
197	The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Research and Therapy, 2011, 13, R174.	3.5	92
198	Pulmonary Disease Associated with Nontuberculous Mycobacteria, Oregon, USA. Emerging Infectious Diseases, 2011, 17, 1760-1761.	4.3	26

#	ARTICLE	IF	CITATIONS
199	Geographic Distribution of Endemic Fungal Infections among Older Persons, United States. <i>Emerging Infectious Diseases</i> , 2011, 17, 1664-1669.	4.3	158
200	Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. <i>Current Opinion in Rheumatology</i> , 2011, 23, 377-384.	4.3	59
201	The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 229-235.	1.9	56
202	Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1199-1209.	1.9	29
203	Let the fog be lifted: screening for hepatitis B virus before biological therapy. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1701-1703.	0.9	23
204	Distinguishing Tuberculosis from Nontuberculous Mycobacteria Lung Disease, Oregon, USA. <i>Emerging Infectious Diseases</i> , 2011, 17, 506-509.	4.3	37
205	Initiation of Tumor Necrosis Factor- α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2331-9.	7.4	305
206	The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1401-1406.	0.9	98
207	River blindness: An old disease on the brink of elimination and control. <i>Journal of Global Infectious Diseases</i> , 2011, 3, 151.	0.5	28
208	Pulmonary Nontuberculous Mycobacterial Disease Prevalence and Clinical Features. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 977-982.	5.6	361
209	Pulmonary disease due to nontuberculous mycobacteria: an epidemiologist's view. <i>Future Microbiology</i> , 2010, 5, 343-345.	2.0	21
210	Preventing tuberculosis and other serious infections in patients starting anti-tumor necrosis factor therapy. , 2010, , 903-905.		0
211	Nontuberculous Mycobacteria Infections and Anti-tumor Necrosis Factor- α Therapy. <i>Emerging Infectious Diseases</i> , 2009, 15, 1556-1561.	4.3	278
212	Nontuberculous Mycobacterial Disease Prevalence and Risk Factors: A Changing Epidemiology. <i>Clinical Infectious Diseases</i> , 2009, 49, e124-e129.	5.8	350
213	Preventing and treating biologic-associated opportunistic infections. <i>Nature Reviews Rheumatology</i> , 2009, 5, 405-410.	8.0	56
214	Mycobacterial and Other Serious Infections in Patients Receiving Anti-tumor Necrosis Factor and Other Newly Approved Biologic Therapies: Case Finding through the Emerging Infections Network. <i>Clinical Infectious Diseases</i> , 2008, 46, 1738-1740.	5.8	174
215	Interferon- γ Release Assays for Diagnosing Mycobacterium tuberculosis Infection in Renal Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1357-1363.	4.5	71
216	A novel assay for screening patients for latent tuberculosis infection prior to anti-TNF therapy. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 456-457.	3.2	3

#	ARTICLE	IF	CITATIONS
217	Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. <i>Journal of Rheumatology</i> , 2008, 35, 1683-5.	2.0	34
218	An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 367-416.	5.6	5,021
219	Nontuberculous mycobacterial disease: updated diagnostic criteria for an under-recognized infectious complication of anti-tumor necrosis factor therapy. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, E1-E1.	3.2	6
220	Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 602-610.	3.2	242
221	The reliability of anterior segment lesions as indicators of onchocercal eye disease in Guatemala. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 1058-62.	1.4	11
222	Tuberculosis associated with therapy against tumor necrosis factor $\hat{\pm}$. <i>Arthritis and Rheumatism</i> , 2005, 52, 2968-2974.	6.7	110
223	Epidemic and sporadic cases of nontuberculous mycobacterial keratitis associated with laser in situ keratomileusis. <i>American Journal of Ophthalmology</i> , 2003, 135, 223-224.	3.3	47
224	An Outbreak of Mycobacterial Furunculosis Associated with Footbaths at a Nail Salon. <i>New England Journal of Medicine</i> , 2002, 346, 1366-1371.	27.0	200
225	Mental health in the Oregon Health Plan: fragmentation or integration?. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 1998, 25, 361-386.	2.1	15
226	Nontuberculous mycobacteria infections in patients receiving immunosuppressive agents. , 0 , 238-253.		0
227	COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis. <i>Rheumatology and Therapy</i> , 0 , .	2.3	1